Equities

IDT Australia Ltd

IDT:ASX

IDT Australia Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded766.26k
  • 1 Year change+4.17%
  • Beta1.1965
Data delayed at least 20 minutes, as of May 30 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.

  • Revenue in AUD (TTM)10.36m
  • Net income in AUD-6.55m
  • Incorporated1986
  • Employees156.00
  • Location
    IDT Australia Ltd45 Wadhurst Dr, BoroniaMELBOURNE 3155AustraliaAUS
  • Phone+61 (39) 801-8888
  • Fax+61 (39) 801-8773
  • Websitehttps://en.idtaus.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BPH Energy Ltd345.67k894.65k22.95m2.00k20.410.9868--66.400.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Noxopharm Ltd3.90m-12.13m23.38m1.00k--3.56--5.99-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Acrux Ltd14.46m-709.00k23.55m43.00--4.16--1.63-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Syntara Ltd9.83m-14.26m23.88m107.00--2.65--2.43-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Tryptamine Therapeutics Ltd1.21m-4.32m25.05m----3.72--20.75-0.0162-0.01620.00370.00620.2368-------84.69-66.34-120.26-79.70-----357.70-228.11---21.620.00---18.97138.7329.29--68.45--
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Cann Group Ltd16.45m-29.28m27.12m40.00--0.5339--1.65-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
IDT Australia Limited10.36m-6.55m35.15m156.00--1.52--3.39-0.022-0.0220.0350.06560.37412.393.51---23.64-9.87-26.41-11.5776.3884.42-63.19-24.942.81--0.0907---42.03-11.97-632.59---26.04--
Prescient Therapeutics Ltd697.94k-7.74m36.24m3.00--1.60--51.92-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Little Green Pharma Ltd23.24m-3.14m39.23m----0.483558.711.69-0.011-0.01260.08330.26890.2631.1312.06---3.55---4.01--51.02---13.51--2.03-21.270.0667--------------
LTR Pharma Ltd-100.00bn-100.00bn42.60m----13.43----------0.0451----------------------------0.00---100.00---41.65------
Inoviq Ltd751.54k-6.51m42.79m85.00--2.56--56.93-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
BCAL Diagnostics Ltd3.67m-5.00m44.15m----7.26--12.02-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
Vitura Health Ltd119.67m9.40m46.65m121.004.921.1912.340.38980.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Data as of May 30 2024. Currency figures normalised to IDT Australia Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

26.74%Per cent of shares held by top holders
HolderShares% Held
Sandon Capital Pty Ltd.as of 09 Jun 202350.42m14.35%
Regal Funds Management Pty Ltd.as of 13 Jun 202343.58m12.40%
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.